Table 5.

Agents that can inhibit the autophagy-lysosome pathway in ischemic stroke models.

Agents	Effects on ischemic stroke	Possible mechanisms	Models	References
miR-207 mimics	Protective	Decreasing the expression of cellular lysosome and autophagosome	In vivo	[90]
DDS	Protective	Inhibiting lysosome accumulation	In vivo and in vitro	[91]
DMBC	Protective	Inhibiting the release of cathepsin B from the lysosomes into the cytoplasm	In vivo and in vitro	[92]
Clik148	Protective	Inhibiting the release of cathepsin L from the lysosomes into the cytoplasm and activation of caspase-3	In vivo and in vitro	[93]
3-MA and Wort	Protective	Inhibiting autophagy and stabilizing lysosomal membranes	In vivo and in vitro	[94]
CA074-me	Protective	Inhibiting the release of cathepsin B, preserving lysosomal membrane integrity, and suppressing lysosomal rupture	In vivo	[93, 95]
Fingolimod	Protective	Inhibiting autophagy via the mTOR/p70S6K pathway	In vivo	[96]
Lycium barbarum polysaccharide	Protective	Inhibiting apoptosis and autophagy through the PI3K/Akt/mTOR pathway	In vitro	[97]
Cornin	Protective	Inhibiting autophagy through the PI3K/Akt/mTOR pathway	In vitro	[98]

Abbreviations: DDS: dapsone; DMBC: 2-(3′,5′-dimethoxybenzylidene) cyclopentanone; 3-MA: 3-methyladenine; Wort: wortmannin.